AMPLATZER Cardiac Plug Clinical Trial
Amplatzer Cardiac Plug Clinical Trial
研究概览
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
Los Angeles、California、美国、90048
- Cedars-Sinai Medical Center
-
Los Angeles、California、美国、90017
- Good Samaritan Hospital
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Denver
-
Littleton、Colorado、美国、80120
- South Denver Cardiology Associates
-
-
Georgia
-
Atlanta、Georgia、美国、30308
- Emory Midtown Hospital and Emory University Hospital
-
Atlanta、Georgia、美国
- St. Joseph's Hospital and Research Institute
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- University of Iowa Hospitals & Clinics
-
-
Kentucky
-
Lexington、Kentucky、美国、40506
- University of Kentucky
-
-
Michigan
-
Detroit、Michigan、美国、48202
- Henry Ford Hospital
-
Grand Rapids、Michigan、美国、49503
- Spectrum Health
-
Southfield、Michigan、美国、48075
- Providence Hospital
-
-
Minnesota
-
Saint Cloud、Minnesota、美国、56303
- St. Cloud Hospital/CentraCare Heart and Vascular Clinic
-
Saint Paul、Minnesota、美国、55102
- HealthEast St. Joseph's Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- University of Pennsylvania
-
York、Pennsylvania、美国、17405
- York Hospital
-
-
South Carolina
-
Charleston、South Carolina、美国、29401
- Roper Hospital/PMG Research of Charleston
-
-
Texas
-
Houston、Texas、美国、77030
- Memorial Hermann Hospital
-
-
Wisconsin
-
Wausau、Wisconsin、美国、54401
- Aspirus Heart & Vascular Institute
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subject must have a documented history of paroxysmal, persistent or permanent nonvalvular atrial fibrillation
- Subject must be ≥18 years of age
- Subject must be on warfarin or dabigatran therapy
- Subject must be eligible for long term warfarin or dabigatran therapy
- Subject must have a CHADS(2) score of 2 or greater
Summary of Exclusion Criteria:
- Subject who requires warfarin or dabigatran for a condition other than AF
- Subject who is on clopidogrel or another P2Y12 platelet inhibitor such as prasugrel or ticagrelor
- Subject who has an absolute or relative contraindication to aspirin, or warfarin and dabigatran
- Subject with a New York Heart Association (NYHA) classification equal to IV
- Subject with an implanted or surgical repair atrial septal defect (ASD) device or patent foramen ovale (PFO) device
- Subject with aortic or mitral valve regurgitation of grade 2+ or greater
- Subject with left ventricular ejection fraction (LVEF) ≤30
- Subject with mitral or aortic prosthetic valve
- Subject with a history of hemorrhagic or aneurysmal stroke
- Subject with a history of previous radio frequency (RF) ablation for atrial fibrillation
- Subject with a body mass index (BMI) ≥40
- Subject with a history of acute or recent MI, or unstable angina, or coronary artery bypass graft surgery (within 6 months)
- Subject who is on aspirin dose therapy greater than 81mg/day at time of enrollment
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Device
AMPLATZER Cardiac Plug
|
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
|
|
有源比较器:Optimal Medical Therapy (control)
Warfarin Dabigatran
|
AMPLATZER Cardiac Plug is a percutaneous transcatheter device
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Acute Safety - Procedure Related SAEs From Randomization Through Discharge For Device Arm Only
大体时间:From Randomization to Discharge Visit
|
An analysis comparing the rate of procedure related serious adverse events that occur in the device arm to a performance goal determined from literature reported rates for similar procedural techniques. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm below. The secondary endpoint analysis requirement was removed from the protocol. |
From Randomization to Discharge Visit
|
|
Long-term Safety - Device Arm Only
大体时间:Randomization to 2 year follow-up
|
All-Cause Mortality and Major Bleeds Through 2 years in device arm subjects only. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol. |
Randomization to 2 year follow-up
|
|
Effectiveness Endpoint - Device Arm Only
大体时间:Randomization through 2 year follow up
|
Occurrence of ischemic stroke and peripheral thromboembolism in the device arm. The study as designed was intended to determine the difference in efficacy and safety between the device and control arm (subjects treated with OMT). However, due to early enrollment closure, the three primary endpoints were not analyzed as specified in the original trial protocol. As the Control arm subjects exited the study early, no sufficient data was available to summarize any endpoints. The three primary endpoints as mentioned in the Appendix D of the clinical investigational plan (Revision 06, dated September 2014) were summarized for the Device arm. The secondary endpoint analysis requirement was removed from the protocol. |
Randomization through 2 year follow up
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.